Parexel Shares Popped: What You Need to Know (PRXL)

Parexel Shares Popped: What You Need to Know

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of pharmaceutical research contractor Parexel International (Nasdaq: PRXL ) climbed 10% in early Wednesday trading after its fourth-quarter results and full-year guidance beat Wall Street expectations.

So what: Parexel restructured the early stage part of its clinical research service segment after a disappointing third quarter. Today's market-topping results -- adjusted EPS of $0.10 versus an analyst consensus of $0.07 -- suggest that the turnaround is under way. The stock is steadily coming off its highs for the day, so investors aren't fully convinced yet, but strong bookings are at least making Parexel's near-term profit outlook much easier to count on.

Now what: Don't let this pop prevent you from researching Parexel. Management now sees a fiscal year 2012 profit in the range of $0.95 to $1.14 per share, while analysts had been expecting per-share earnings of $0.93 to $1.10. With the stock still down about 25% over the past three months, betting on that guidance may be a reasonable thing to do.

Interested in more info on Parexel? Add it to your watchlist.

The Steve Jobs Betrayal
You may already know that in the final year of his life, Jobs revealed a stunning betrayal — and told his biographer, "I will spend my last dying breath... and every penny of Apple's $40 billion in the bank to right this wrong." What was it that made Jobs so irate — and why could it make a few in-the-know investors some major profits over the coming months and years?

Enter your email address below to find out what made Jobs so enraged!

Fool contributor Brian Pacampara owns no position in any of the companies mentioned. Try any of our Foolish newsletter services free for 30 days.

We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Fool's disclosure policy always gets a perfect score.

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment icon found on every comment.